People with schizophrenia are excluded from psychedelic research

Psychedelic side effects, including worsening mental health for some patients, give pause

This article explores whether the therapeutic potential of psychedelic drug use is really as good as current research suggests. Scientists are exploring its applications for conditions ranging from the existential crisis that can accompany terminal diagnoses to chronic mental health conditions, including anxiety and PTSD.

Mental health applications of psychedelics

Scientists are investigating psilocybin, ketamine, LSD, and MDMA (also known as ecstasy) as potential treatments for mental health issues. These drugs enable an altered state of consciousness, which can have beneficial or harmful impacts depending on the nature of the experience. Research suggests these drugs can be effective in treating substance use disorders, mental health conditions, including depression and anxiety, and psychiatric disorders, including schizophrenia.

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

How psilocybin could transform mental health treatment

How magical are magic mushrooms, at least where depression is concerned? Some 24 volunteers participated in a study to evaluate the efficacy of using psilocybin in combination with psychotherapy to treat individuals suffering from depression. While some controversies remain about its use—psilocybin is known to cause psychosis sometimes—some scientists think the benefits outweigh the risks.

How Western psychedelics research fell to the wayside

Psychedelics' modern era began when LSD was discovered in the 1930s. By the 1950s, clinical trials were underway. US user experimentation outside of medical settings (and high-profile violence, like the Manson murders) inspired negative attitudes toward psychedelics, leading to use restrictions that prohibited companies from patenting psychedelic compounds. This strangled psychedelics' profitability until the 1990s when the government loosened its grip and psychedelics research began seeing a resurgence.

Psychedelic drugs are having a scientific renaissance

After decades of repression, psychedelic research is making a resurgence. Hear from a host of experts in this 20-minute video on what that could mean for the future of mental health. The current science on psychedelics believes LSD can cause a particular brain network to quiet or deactivate.

Psychedelic therapy's ethical guidelines (or lack thereof)

With a checkered history of misconduct, how will psychedelic-assisted therapists be held accountable in the emerging legal field? This article explores the nascent field's need for ethical guidelines and clear protection of patient rights when therapeutic breakthroughs teeter "on the edge of consent."

Oregon voters in 2020 greenlit adult use of psilocybin—the active ingredient in magic mushrooms—in state-licensed centers, and a 2026 analysis indicates the program has good safety and satisfaction data.

Psychedelics interact with neurotransmitter systems to alter one's perception

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

The commercial and therapeutic potential of psychedelics

A 2006 study into the potential therapeutic benefits of psychedelics sparked a renewed interest in the field of psychedelic research, a development that has cascaded into commercialized ventures and experiences. This article details how growing research into the psychological benefits of psychedelics is matched by the rise of anecdotal reports, book deals, businesses, and corporate claims seeking to capitalize on psychedelic potential.

Schizophrenia is challenging to diagnose and treat

The disorder is diagnosed by a clinician who observes behaviors and medical history and may run additional tests to rule out other explanations for symptoms including physical injury or other mental health disorders. But, ultimately, it's largely a diagnosis of exclusion—since there is no definitive test for the disease. Antipsychotic medications can help control its symptoms for some patients, but there is no cure for schizophrenia.

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

How psychedelics can potentially reinvent learning

Critical periods, discovered in the early 20th century, describe a period when someone is incredibly sensitive to their environment, and any information learned can stick with them for life. Some researchers argue these states can be "reopened" via psychedelics, which put the mind into a malleable state that can potentially be used to treat conditions ranging from lazy eyes to PTSD.

An overview of modern clinical research on LSD

Researchers have determined that LSD, taken in a medical setting, decreases anxiety related to "life-threatening disease," reduces brain reactivity to fearful faces, increases the meaning and emotional response derived from music, and more. No complications of LSD administration have been observed in medical settings, though acute adverse effects, including exhaustion, nausea, and difficulty concentrating.

Can microdosing improve mental health?

Animal studies involving microdoses of psilocybin, the psychoactive component in magic mushrooms and ketamine, found it helped to alleviate anxiety and inflammation, an immune response that can cause damage when chronically active. Human studies are ongoing. In at least one double-blind study, where researchers and patients don't know who got a placebo versus the real thing, about half of the participants incorrectly guessed they had been given placebos.

Less than 1% of people globally have schizophrenia, a syndrome strongly linked to genetics

Schizophrenia's causes remain largely unknown, though scientists suggest it's caused by multiple factors. Its symptoms include disruption of thought processes rather than the exhibiting of multiple personalities. This brief video provides an overview of the condition.

Could this pseudo-psychedelic VR experience decrease symptoms of depression?

Researchers report that virtual reality and psychedelics may be leave users with similar insights and therapeutic benefits. Try out this free psychedelic virtual reality experience to see if this holds true for you. According to the program’s creators, a study into the efficacy of this 45-minute experience indicates it may help alleviate symptoms of mild to moderate depression.

Studies of psychedelic use may help shed light on the nature of consciousness

The nature of consciousness—what it is, where it comes from, and how it manifests as moment-to-moment experience—remains under debate by scientists. Recent studies show psychedelics were found to boost low-frequency brain signals known as delta waves, a behavior also seen during dream states.

Traumatic childhood experiences heighten the risk of developing schizophrenia

Clinically termed as "adverse childhood experiences," events such as physical or mental abuse or the death of loved ones have repeatedly been linked to an increase in rates of developing schizophrenia later in life. The reasons behind this link remain under investigation.

What can psychedelics teach us about dying?

Psychedelics have made their way into the world of licensed mental healthcare, and the drugs have been proven to help people process and lessen anxiety and depression. What does this mean for people with terminal illnesses who are afraid of death?

LSD fueled a countercultural movement before evolving into a potential therapeutic

As the use of recreational psychedelics became common, authorities were quick to claim LSD had lasting adverse effects, criminalizing the drug and halting scientific study for decades. Over time, LSD's reputation shifted from a potential source of enlightenment to a dangerous drug that could dim a person's future, and back to a possible therapeutic compound.

80% of schizophrenia cases may be inherited

Some research suggests that anywhere between 60% and 80% of people with schizophrenia had genes that predisposed them to the syndrome. That high rate has fueled interest in further exploration of what environmental and lifestyle factors cause some people with that genetic risk to develop the disease when others with the same genetic risks do not.

How to avoid a 'bad trip' advice includes relaxing your mind if you experience scary things and not fighting the feeling

In this video, Michael Pollan, author of "This Is Your Mind On Plants," underscores the gaps in existing understanding about the substances and recommends only taking guided experiences, for safety and help. He tackles how psychedelics work, explains microdosing and psychedelic risks, how the substances could be used to treat addiction, and the history of psychedelic stigma.

Are psychedelics legal in your state?

The answer is usually more complicated than a simple yes or no. This resource includes a state-by-state and international breakdown of current psychedelics legislation and reform. As of November 2023, psychedelics are fully illegal in 18 states, though there still may be religious or medical exemptions depending on the drug in question. Legislation reform and decriminalization efforts are ongoing.

Schizophrenia is being studied with pea-sized 'mini-brains'

Brain organoid research is enabling researchers to study distinct electrical firing patterns associated with schizophrenia. These "mini-brains" that are constructed in the lab from patients' cells could lead to better diagnosis approaches and drug development.

People with schizophrenia typically die 9 years earlier than the general population

The syndrome, which affects roughly 1 in 233 adults, is often associated with other serious health issues, including cardiovascular, metabolic, and infectious diseases, which may contribute to early deaths. The side effects of long-term antipsychotic medications also may influence the mortality timing—weight gain, for example, is a common side effect of the drugs and can contribute to cardiovascular issues.

Misfired motor signals may explain why many people with schizophrenia hear voices

Up to 80% of schizophrenia patients may have auditory hallucinations. Recent research concluded that this symptom may be from misfired motor signals that feed into each other, essentially failing to suppress certain sensory neural activities and that resulting overexcitment fuels hallucinations. The finding suggests that, one day, magnetic pulses might be used to stimulate specific nerves to better regulate the errant signals and reduce or stop hallucinations. (Some users may encounter a paywall.)

The neurobiology of meaningfulness: the benefits of psychedelics

Psychedelics produce powerful emotions in its users, including a profound sense of meaningfulness. The philosopher William James called this sense "noetic" in the late 19th century, but for decades researchers avoided studying the effects of such drugs on the brain. However, the recent resurgence in psychedelic research has heightened interest in the relationship between this noetic sense resulting from the therapeutic use of drugs. Learn what researchers have found out here.

How four types of psychedelics affect the brain

Brain imaging shows that ayahuasca, MDMA, DMT, and psilocybin profoundly affect neural activity, giving rise to higher states of introspection and consciousness. This article details exactly how each of these drugs physically affects the brain and what that means for mental health treatment. Some of these drugs quiet the brain or trigger the release of neurochemicals associated with mood regulation and learning.

How can octopuses and MDMA help scientists understand the human brain?

Research shows that psychedelics may induce something called "critical periods" in the adult brain, which can make our brains more open to learning and changing, like they once were back in early childhood. Psychedelics similarly change how social creatures like octopuses behave, which demonstrates that these animals could help us better understand our own neurobiology.

Australian psychiatrists already prescribe psilocybin and MDMA for depression and PTSD

The country green lighted the treatments for July 1, 2023, onward, with MDMA—ectasy—as a post-traumatic stress disorder treatment, and psilocybin—magic mushrooms—as an option for people with treatment-resistant depression.

Watch veterans experience psilocybin at a Mexican clinic and discuss the aftermath

This "60 Minutes" episode from 2025 follows nine veterans attending a week-long psychedelic retreat to treat their PTSD. Most of the vets say the experience at the Mexican clinic was life-changing. But results were mixed: One veteran reported he was scared and that the experience worsened his mental health overall.

People with schizophrenia have triple the risk of developing diabetes

It remains contentious if something inherent about the disease or antipsychotics' side effects (weight gain) are mostly to blame. Some newly diagnosed schizophrenia patients already have insulin resistance, raising questions about if patients' brains are getting enough energy from glucose, and if dietary changes—like a high-fat, low-carbohydrate, moderate-protein diet—may help alleviate symptoms.

Using psychedelics to manage a cancer diagnosis

Dr. Roland Griffiths helped lead the revival of psychedelic research, often prescribing the use of psilocybin to address severe depression or anxiety in patients. This podcast explores how Griffiths leaned on his own career after being diagnosed with cancer and facing the prospect of death.

Why might someone want to stay in psychosis?

Author Abigail Gosselin writes that her verbal auditory hallucination, often assumed by others to be harmful or threatening in nature, offered a salve to loneliness, even as it told her to kill herself. This perceived benefit and others Gosselin shares offer insight into why people in psychosis may struggle to adhere to treatment and medication plans.

Psychedelics set off a flurry of brain activity that may permanently alter it

The brain seems to experience a sharp increase in communication between areas that generally don't interact. New research suggests a thin, sheet-like gray matter structure tucked deep within the brain, between the insular cortex and striatum, may be the key to this change. The area is centrally located and home to many of the receptors that psychedelics target, potentially rewiring the brain and rewriting thought patterns.

Schizophrenia increases heat death risks in several complex ways

Evidence shows that people with schizophrenia have an inherently harder time regulating internal body temperatures. They may also struggle to find safe shelter during extreme heat, and their prescribed antipsychotic medications often have dehydrating effects, collectively elevating the risk of heat-related illness and death, as illustrated by this article that focuses on the final days of Stephan Goodwin's life in 2022. (Some users may encounter a paywall.)

Schizophrenia literally means 'split mind'—a reference to patients' break with reality

Contrary to the name, patients do not have multiple personalities. Rather, the split mind refers to the sufferers' inability to distinguish reality from hallucinations when they are aware and awake. Cognitive difficulties, including challenges focusing and communicating are also common among those with schizophrenia, as well as auditory and visual hallucinations.

Psychedelic DMT—part of ayahuasca—shows antidepressant promise in small clinical trial

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

Schizophrenia symptoms, like psychosis, often first emerge among young adults

A combination of genetics, significant brain changes to the frontal cortex, and hormonal changes during young adulthood—late teens to early 30s—result in schizophrenic symptoms often showing up during this period. The stress of life changes at that age may also be a contributing factor.

Schizophrenia symptoms often appear suddenly

Schizophrenia is a particularly shocking mental illness because its symptoms may appear seemingly without any prior signs of illness after a person has had no symptoms for the first couple of decades of their life. Among teens, symptoms may look like typical adolescent behaviors—withdrawal, being irritable, and having trouble sleeping.

Deinstitutionalization in the 20th century unintentionally led to the incarceration of schizophrenia patients

Activism to shut down problematic asylums in the mid-20th century led to the community release of many patients with severe mental illnesses, including schizophrenia, but without adequate support, this deinstitutionalization in the 1960s and 1970s led to a significant increase in patients with schizophrenia ending up in prisons and homeless shelters.

Gene expression patterns are similar between ASD, schizophrenia, and bipolar disorder

Postmortem brain tissue analysis suggests there are genetic and epigenetic similarities between individuals with autism, schizophrenia and bipolar disorder. All three conditions appeared to have activation of genes in astrocytes and suppression of specific genes that function at the junction between neurons, called synapses. (Some users may encounter a paywall.)

Psychedelic compounds: a visual library

However psychedelic experiences manifest, they all begin with the presence of psychoactive compounds. Learn about their various chemical compositions in this structural library of psychedelic compounds. Clicking on an entry will take readers to a new page where they can learn about the chemistry and pharmacology of each compound, as well as the drug's possible applications.

LSD-like drugs may inspire new antidepressants

LSD and psilocybin have shown promise as antidepressants. Using a virtual library of similar chemical compounds, researchers determined via animal studies that two molecules inspired by LSD have antidepressant effects without any associated hallucinogenic experience. These molecules were found to be 40 times more potent than the common antidepressant fluoxetine, also known as Prozac, with antidepressant effects lasting up to 21 days.

An account of unethical behavior by psychedelic guides

Ethical guidelines and protections have a gossamer grasp in the underground psychedelics movement. This 34-minute podcast episode delves into patterns of deception and abuse by movement leaders through one source's deeply personal tale. This episode, which involves descriptions of sexual violence, is one of many in New York Magazine's Power Trip series, a nine-part investigation into the darker side of the psychedelic renaissance.

Some data links schizophrenia to older paternal age and birth complications

Yet both associations are not yet considered firm enough to definitively be causative. Schizophrenia is a multi-causal syndrome and a mixture of factors, including genetics, are widely believed to be behind its development.

Circadian rhythm disruption can influence various mental health disorders

This 2020 research overview surveys the relationship between disrupted circadian clocks and disorders including schizophrenia, anxiety, and bipolar disorder. It incorporates findings and therapeutic approaches drawing from human night shift studies and jet lag studies alongside animal research.

An LSD scientist's role in a US mind control project

Within a decade of LSD's discovery, the US government had launched a secret initiative involving hypnosis and hallucinogens. LSD researcher Louis Jolyon West conducted experiments for the CIA's MKUltra project, which focused on the potential of mind control. He later took part in a criminal trial that hinged on testimony whose sourcing was seemingly inspired by MKUltra experiments. This article explores light shed by West's personal archive.

A new schizophrenia healthcare model is giving patients more of a role in shaping their own treatments, with good results.